2 Central nervous system opportunistic infections

HIV Medicine

Volumn 12, Issue SUPPL. 2, 2011, Pages 8-24

  Nelson, M ^a   Manji, H ^b   Wilkins, E ^c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Central nervous system opportunistic infections; Cryptococcus neoformans; Cytomegalovirus (CMV); Progressive multifocal leukoencephalopathy; Toxoplasmosis

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; ATAZANAVIR; CIDOFOVIR; DAPSONE; DIDANOSINE; EFAVIRENZ; ETRAVIRINE; FLUCONAZOLE; FLUCYTOSINE; FOLINIC ACID; FOSCARNET; GANCICLOVIR; ITRACONAZOLE; LOPINAVIR; MARAVIROC; NEVIRAPINE; POSACONAZOLE; PYRIMETHAMINE; RITONAVIR; SULFADIAZINE; TENOFOVIR; VALGANCICLOVIR; VORICONAZOLE; ZIDOVUDINE;

ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; CYTOMEGALOVIRUS INFECTION; ENCEPHALITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LEUKOENCEPHALOPATHY; LOADING DRUG DOSE; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RADICULOPATHY; TOXOPLASMOSIS;

EID: 80051887909     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00944_3.x     Document Type: Article

References (128)

1. Pozniak AL, Collins S, Coyne KM et al. British HIV Association guidelines for the treatment of TB/HIV co-infection 2009. Available at: (last accessed 16 December 2009).
2. Bower M, Collins S, Cottrill C et al. AIDS Malignancy Subcommittee. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med 2008; 9: 336-388.
3. Dismukes WE. Cryptococcal meningitis in patients with AIDS. J Infect Dis 1988; 157: 624-628.
4. Chariyalertsak S, Sirisanthana T, Saengwonloey O, Nelson KE. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994-1998: regional variation and temporal trends. Clin Infect Dis 2001; 32: 955-962.
5. McCarthy KM, Morgan J, Wannemuehler KA et al. Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS 2006; 20: 2199-2206.
6. Sacktor N, Lyles RH, Skolasky R et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001; 56: 257-260.
7. Neuenburg JK, Brodt HR, Herndier BG et al. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31: 171-177.
8. Goldman DL, Khine H, Abadi J et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 2001; 107: E66.
9. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS -100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8: 515-548.
10. Chaturvedi S, Dyavaiah M, Larsen RA, Chaturvedi V. Cryptococcus gattii in AIDS patients, southern California. Emerg Infect Dis 2005; 11: 1686-1692.
11. Hoang LM, Maguire JA, Doyle P et al. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J Med Microbiol 2004; 53: 935-940.
12. Levitz SM. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 1991; 13: 1163-1169.
13. Ellis DH, Pfeiffer TJ. Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol 1990; 28: 1642-1644.
14. Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989; 321: 794-799.
15. Lin X, Heitman J. The biology of the Cryptococcus neoformans species complex. Annu Rev Microbiol 2006; 60: 69-105.
16. Shea JM, Kechichian TB, Luberto C, Del Poeta M. The cryptococcal enzyme inositol phosphosphingolipid-phospholipase C confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system. Infect Immun 2006; 74: 5977-5988.
17. Nelson MR, Bower M, Smith D et al. The value of serum cryptococcal antigen in the diagnosis of cryptococcal infection in patients infected with the human immunodeficiency virus. J Infect 1990; 21: 175-181.
18. Dimino-Emme L, Gurevitch AW. Cutaneous manifestations of disseminated cryptococcosis. J Am Acad Dermatol 1995; 32: 844-850.
19. French N, Gray K, Watera C et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16: 1031-1038.
20. Driver JA, Saunders CA, Heinze-Lacey B, Sugar AM. Cryptococcal pneumonia in AIDS: is cryptococcal meningitis preceded by clinically recognizable pneumonia? J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 168-171.
21. Committee for the Japanese Respiratory Society Guidelines in Management of Respiratory Infections. Pneumonia in immunosuppressed patients. Respirology 2004; 9 (SUPPL. 1): S25-S29.
22. Shafiq M, Schoch PE, Cunha BA, Iliescu MD. Nocardia asteroides and Cryptococcus neoformans lung abscess. Am J Med 2000; 109: 70-71.
23. Thomas R, Christopher DJ, Kurien S et al. Cryptococcal pleural effusion in acquired immune deficiency syndrome-Diagnosis by closed pleural biopsy. Respiratory Medicine Extra 2006; 2: 7-9.
24. Currie BP, Freundlich LF, Soto MA, Casadevall A. False-negative cerebrospinal fluid cryptococcal latex agglutination tests for patients with culture-positive cryptococcal meningitis. J Clin Microbiol 1993; 31: 2519-2522.
25. Laurenson IF, Ross JD, Milne LJ. Microscopy and latex antigen negative cryptococcal meningitis. J Infect 1998; 36: 329-331.
26. Eng RH, Person A. Serum cryptococcal antigen determination in the presence of rheumatoid factor. J Clin Microbiol 1981; 14: 700-702.
27. Sadamoto S, Ikeda R, Nishikawa A, Shinoda T. Evidence for interference by immune complexes in the serodiagnosis of cryptococcosis. Microbiol Immunol 1993; 37: 129-133.
28. McManus EJ, Jones JM. Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol 1985; 21: 681-685.
29. Aberg JA, Mundy LM, Powderly WG. Pulmonary cryptococcosis in patients without HIV infection. Chest 1999; 115: 734-740.
30. Rex JH, Pfaller MA, Walsh TJ et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643-658.
31. Dannaoui E, Abdul M, Arpin M et al. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 2006; 50: 2464-2470.
32. Aller AI, Martin-Mazuelos E, Lozano F et al. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 2000; 44: 1544-1548.
33. Saag M, Powderly WG, Cloud GA et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326: 83-89.
34. Bennett JE, Dismukes W, Duma RJ et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979; 301: 126-131.
35. Dismukes WE, Cloud G, Gallis HA et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987; 317: 334-341.
36. van der Horst C, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337: 15-21.
37. Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for the treatment of cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990; 113: 183-187.
38. Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993; 17: 837-842.
39. Brouwer AE, Rajanuwong A, Chierakul W et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363: 1764-1767.
40. Saag MS, Cloud GA, Graybill JR et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999; 28: 291-296.
41. Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-693.
42. Leenders AC, Reiss P, Portegies P et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997; 11: 1463-1471.
43. Larsen RA, Bozzette SA, Jones B et al. Fluconazole combined with flucytosine for cryptococcal meningitis in persons with AIDS. Clin Infect Dis 1994; 19: 741-745.
44. Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, Kanyemba C, Jarvis JN, Jaffar S, Hosseinipour MC, Kamwendo D, van der Horst CM, Harrison TS. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 2010; 50: 338-344.
45. de Gans J, Portegies P, Tiessens G et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992; 6: 185-190.
46. Brummer E, Kamei K, Miyaji M. Anticryptococcal activity of voriconazole against Cryptococcus neoformans var. gatti vs var. neoformans: comparison with fluconazole and effect of human serum. Mycopathologia 1998; 142: 3-7.
47. Pitisuttithum P, Negroni R, Graybill JR et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56: 745-755.
48. Shen YZ, Wang JR, Lu HZ. Voriconazole in an infant with cryptococcal meningitis. Chin Med J 2008; 121: 286-288.
49. Maligie MA, Selitrennikoff CP. Cryptococcus neoformans resistance to echinocandins: (1, 3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother 2005; 49: 2851-2856.
50. Newton PN, Thai le H, Tip NQ et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002; 35: 769-772.
51. Graybill JR, Sobel J, Saag M et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000; 30: 47-54.
52. Bozzette SA, Larsen RA, Chiu J et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1991; 324: 580-584.
53. Pitisuttithum P, Tansuphasawadikul S, Simpson AJ et al. A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B. J Infect 2001; 43: 226-233.
54. Powderly WG, Saag MS, Cloud GA et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992; 326: 793-798.
55. Nelson MR, Fisher M, Cartledge J et al. The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS 1994; 8: 651-654.
56. Aberg JA, Watson J, Segal M, Chang LW. Clinical utility of monitoring serum cryptococcal antigen (sCRAG) titers in patients with AIDS-related cryptococcal disease. HIV Clin Trials 2000; 1: 1-6.
57. Dromer F, Mathoulin S, Dupont B et al. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. Clin Infect Dis 1996; 22 (SUPPL. 2): S154-S160.
58. Pappas PG, Perfect J, Larsen RA et al. Cryptococcosis in HIV-negative patients: analysis of 306 cases. 36th Annual Meeting of the Infectious Diseases Society of America, Denver, CO, November, 1998. [Abstract 101].
59. Yamaguchi H, Ikemoto H, Watanabe K et al. Fluconazole monotherapy for cryptococcosis in non-AIDS patients. Eur J Clin Microbiol Infect Dis 1996; 15: 787-792.
60. Chang LW, Phipps WT, Kennedy GE, Rutherford GW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev 2005; Issue 3. Art. No.: CD004773. DOI: DOI: 10.1002/14651858.CD004773.pub2.
61. Ives N, Gazzard BG, Easterbrook PJ. Changing pattern of AIDS defining illnesses with introduction of highly active antiretroviral therapy in a London clinic. J Infect 2001; 42: 134-139.
62. Makadzange A, Ndhlovu C, Takarinda K et al. Early vs delayed ART in the treatment of cryptococcal meningitis in Africa. 16th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2009. [Abstract 36cLB].
63. Lortholary O, Fontanet A, Mémain N et al. for the French Cryptococcosis Study Group Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19: 1043-1049.
64. Shelburne SA 3rd, Darcourt J, White AC Jr et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40: 1049-1052.
65. Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis 2002; 35: e128-e133.
66. Vibhagool A, Sungkanuparph S, Mootsikapun P et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003; 36: 1329-1331.
67. Martinez E, Garcia-Viejo MA, Marcos MA et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS 2000; 14: 2615-2617.
68. Mussini C, Pezzotti P, Miró JM et al. International Working Group on Cryptococcosis. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis 2004; 38: 565-571.
69. Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, Wit FW, Ledergerber B, Lundgren JD, Furrer H. European HIV Cohorts. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137: 239-250.
70. Lindstrom I, Kaddu-Mulindwa DH, Kironde F, Lindh J. Prevalence of latent and reactivated Toxoplasma gondii parasites in HIV patients from Uganda. Acta Trop 2006; 100: 218-222.
71. Hill D, Dubey JP. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microb Infect 2002; 8: 634-640.
72. Derouin F, Leport C, Pueyo S et al. Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV infected patients. ANRS 005/ACTG 154 Trial group. AIDS 1996; 10: 1521-1527.
73. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med 1992; 327: 1643-1648.
74. Levy RM, Mills CM, Posin JP et al. The efficacy and clinical impact of brain imaging in neurologically symptomatic AIDS patients: a prospective CT/MRI study. J Acquir Immune Defic Syndr 1990; 3: 461-471.
75. Offiah CE, Turnbull IW. Imaging appearances of intracranial CNS infections in adults HIV and AIDS patients. Clin Radiol 2006; 61: 393-401.
76. Steinmetz H, Arendt G, Hefter H et al. Focal brain lesions in patients with AIDS: aetiologies and corresponding radiological patterns in a prospective study. J Neurol 1995; 242: 69-74.
77. Miller RF, Hall-Craggs MA, Costa DC et al. Magnetic resonance imaging, thallium-201 SPET scanning, and laboratory analyses for discrimination of cerebral lymphoma and toxoplasmosis in AIDS. Sex Transm Infect 1998; 74: 258-264.
78. Skiest DJ, Erdman W, Chang WE et al. SPECT thallium-201 combined with Toxoplasma serology for the presumptive diagnosis of focal central nervous system mass lesions in patients with AIDS. J Infect 2000; 40: 274-281.
79. Cingolani A, de Luca A, Ammassari A et al. PCR detection of Toxplasma gondii DNA in CSF for the differential diagnosis of AIDS-related focal brain lesions. J Med Microbiol 1996; 45: 572-576.
80. Schoondermark-van de Ven E, Galama J, Kraaijeveld C et al. Value of the polymerase chain reaction for the detection of Toxoplasma gondii in cerebrospinal fluid from patients with AIDS. Clin Infect Dis 1993; 16: 661-666.
81. Vidal JE, Colombo FA, de Oliveira AC, Focaccia R, Pereira-Chioccola VL. PCR assay using cerebrospinal fluid for diagnosis of cerebral toxoplasmosis in Brazilian AIDS patients. J Clin Microbiol 2004; 42: 4765-4768.
82. Luft BJ, Hafner R, Korzun AH et al. Toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome. N Engl J Med 1993; 329: 995-1000.
83. Katlama C, De Wit S, O'Doherty E et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996; 22: 268-275.
84. Dannemann B, McCutchan JA, Israelski D et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomised trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulphadiazine. Ann Intern Med 1992; 116: 33-43.
85. Jordan MK, Burstein AH, Rock-Kress D, Alfaro RM, Pau AK, Kovacs JA, Piscitelli SC. Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48: 635-637.
86. Podzamczer D, Miró JM, Ferrer E et al. Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients* Spanish Toxoplasmosis Study Group. Eur J Clin Microbiol Infect Dis 2000; 19: 89-95.
87. Chirgwin K, Hafner R, Leport C et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clin Infect Dis 2002; 34: 1243-1250.
88. Torre D, Casari S, Speranza F et al. Randomised trial of trimethoprim-sulphamethoxazole versus pyrimethamine-sulphadiazine for therapy of toxoxplasmic encephalitis in patients with AIDS. Antimicrob Agents Chemother 1998; 42: 1346-1349.
89. Béraud G, Pierre-François S, Foltzer A et al. Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994-2006. Am J Trop Med Hyg 2009; 80: 583-587.
90. Ribera E, Fernandez-Sola A, Juste C et al. Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoxplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis 1999; 29: 1461-1466.
91. Girard PM, Landman R, Gaudebout C et al. for the PRIO Study Group. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. NEJM 1993; 328: 1514-1520.
92. Rodríguez-Rosado R, Soriano V, Dona C, González-Lahoz J. Opportunistic infections shortly after beginning highly active antiretroviral treatment. Antivir Therapy 1998; 3: 229-231.
93. Furrer H, Opravil M, Bernasconi E et al. Stopping primary prophylaxis in HIV-1 infected patients at high risk of toxoplasma encephalitis. Lancet 2000; 355: 2217-2218.
94. Soriano V, Dona C, Rodriguez-Rosado R et al. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2000; 14: 383-386.
95. Miro JM, Lopez JCGESIDA 04/98 Study Group et al. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. Clin Infect Dis 2006; 4: 79-89.
96. Stolt A, Sasnauskas K, Koskela P, Lehtinen M, Dillner J. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003; 84: 1499-1504.
97. Elphick G, Querbes W, Jordan J et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004; 306: 1380-1383.
98. d'Arminio Monforte A, Cinque P, Mocroft A et al. Changing incidence of central nervous system diseases in the EuroSIDA Cohort. Ann Neurol 2004; 55: 320-328.
99. Mocroft AAntiretroviral Therapy Cohort Collaboration. Clinical endpoints for randomized clinical trials: all AIDS-defining conditions are not created equal. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 2007. [Abstract 80].
100. Ammassari A, Cingolani A, Pezzotti P et al. AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology 2000; 55: 1194-1200.
101. Cinque P, Bossolasco S, Brambilla AM et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 2003; 9 (SUPPL. 1): 73-80.
102. Cinque P, Scarpellini P, Vago L, Linde A, Lazzarin A. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS 1997; 11: 1-17.
103. Marzocchetti A, Di Giambenedetto S, Cingolani A et al. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 2005; 43: 4175-4177.
104. Wyen C, Hoffmann C, Schmeisser N et al. Progressive multifocal leukoencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. J Acquir Immune Defic Syndr 2004; 37: 1263-1268.
105. Marra C, Rajicic N, Barker D et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 2002; 16: 1791-1797.
106. De Luca A, Ammassari A, Pezzotti P et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 2008; 22: 1759-1767.
107. Berenguer J, Miralles P, Arrizabalaga J et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2003; 36: 1047-1052.
108. Hall C, Dafni U, Simpson D et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med 1998; 338: 1345-1351.
109. Gasnault J, Lanoy E, Bentata M, Guiguet M, Costagliola D. Intracerebral penetrating ART are more efficient on survival of HIV+ patients with progressive multifocal leucoencephalopathy. (ANRS CO4 - FHDH). 15th Conference on Retroviruses and Opportunistic Infections, February 2008, Boston, MA, USA. Abstract 385.
110. Antinori A, Cingolani A, Lorenzini P et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003; 9 (Supp.l 1): 47-53.
111. Griffiths P. Cytomegalovirus infections of the central nervous system. Herpes 2004; 11 (SUPPL. 2): 95A-104A.
112. Anders HJ, Goebel F. Neurological manifestations of cytomegalovirus infection in the acquired immunodeficiency syndrome. Int J STD AIDS 1999; 10: 151-161.
113. McCutchan JA. Cytomegalovirus infections of the nervous system in patients with AIDS. Clin Infect Dis 1995; 20: 747-754.
114. Bylsma SS, Achim CL, Wiley CA et al. The predictive value of cytomegalovirus retinitis for cytomegalovirus encephalitis in acquired immunodeficiency syndrome. Arch Ophthalmol 1995; 113: 89-95.
115. Clifford DB, Arribas JR, Storch GA, Tourtellote W, Wippold FJ. Magnetic resonance brain imaging lacks sensitivity for AIDS associated cytomegalovirus encephalitis. J Neurovirol 1996; 2: 397-403.
116. Gozlan J, Salord JM, Roullet E et al. Rapid detection of cytomegalovirus DNA in cerebrospinal fluid of AIDS patients with neurologic disorders. J Infect Dis 1992; 166: 1416-1421.
117. Wolf DG, Spector SA. Diagnosis of human cytomegalovirus central nervous system disease in AIDS patients by DNA amplification from cerebrospinal fluid. J Infect Dis 1992; 166: 1412-1415.
118. Cinque P, Vago L, Brytting M et al. Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. J Infect Dis 1992; 166: 1408-1411.
119. Martin DF, Sierra-Madero J, Walmsley S et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346: 1119-1126.
120. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. N Engl J Med 1992; 326: 213-220.
121. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomised, controlled trial. Studies of ocular complications of AIDS Research Group, AIDS Clinical Trials Group. Ann Intern Med 1997; 126: 264-274.
122. Anduze-Faris B, Fillet AM, Gozlan J et al. Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. AIDS 2000; 14: 517-524.
123. Anders HJ, Weiss N, Bogner JR, Goebel FD. Ganciclovir and foscarnet efficacy in AIDS-related CMV polyradiculopathy. J Infect 1998; 36: 29-33.
124. Miller RG, Storey JR, Greco CM. Ganciclovir in the treatment of progressive AIDS-related polyradiculopathy. Neurology 1990; 40: 569-574.
125. Spector S, McKinley G, Lalezari J et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996; 334: 1491-1497.
126. Feinberg JE, Hurwitz S, Cooper D et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis 1998; 177: 48-56.
127. Youle M, Gazzard B, Johnson M et al. Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. AIDS 1994; 8: 641-649.
128. Gazzard BGBHIVA Treatment Guidelines Writing Group. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608.